{"efta_number": "EFTA02275605", "page_count": 3, "url": "https://epstein-data.com/EFTA02275605", "pdf_url": "https://epstein-data.com/pdf/EFTA02275605.pdf", "pages": [{"efta_number": "EFTA02275605", "page_number": 0, "text_content": "To: \nrnYahoo•conll \nFrom: \nLesley Groff \nSent \nThur 1/17/2019 5:18:48 PM \nSubject: Re: Catching Up \nHI \n...all is good! I will forward this on for you... \nHope all is well with you too. \nLesley \nOn Jan 17 2(\n. \nat \n:19 PMir \nwrote: \nHi Lesley, \nI hope you're well! It's been a while since I was in touch! I emailed Jeffrey and Rich last \nnight but wasn't sure that they still use the email addresses that I have. Thank you \nfor forwarding this onto to them if you can. \nI hope to see you soon! My cell is: \nif you ever need to reach me. \nall the very best, \n<1506365439123blobjpg> \n \nFo \nFrom: \n<ealbraith\nTo: jeevacationearnail.com <jeevacatson(d!qmail corn>; \nMiNiMiliNNOMM \nSent: Wednesday, January 16, 2019, 11:22:06 PM EST \nEFTA_R1_01089429 \nEFTA02275605\n", "char_count": 760}, {"efta_number": "EFTA02275605", "page_number": 1, "text_content": "Subject: Catching Up \nDear Jeffrey \nI hope you've been well. I wanted to update you on what I've been up to for the last two \nyears. I was also hoping to talk with you to see if I might use the foundation's \nLexington office conference room from time to time for my work and what I could \nprovide in exchange for that. I am cc'ing Rich because I'm not sure if you still use \nthis email? \nSince working for your foundation, I continued to publish as a journalist writing mostly \nabout genetic vectors (Newsweek, Techonomy etc). I then set up an LLC that \nprovides business development for labs that have reversed age-driven or \ndegenerative diseases. Most of the therapies are genetic vectors, and have to show \nremarkable results at the mouse level and beyond. Regenerative medicine is a \nrapidly evolving field, and one that forces the medical industry to shift their focus \nfrom addressing symptoms of disease to fundamental evolutionary shortfalls. \nSo far, I placed a genetic vector at the National Institute of Medicine in France (that \nreversed glaucoma in mice using the neuroglobin gene) under formal licence \nreview with a publicly traded pharma group here in the US. And I am collaborating \nwith a lab at the University of Pittsburgh that has reversed cirrhosis/ end stage liver \ndisease in rats using the master transcription gene in hepatocytes. The concept of \nthe latter gene vector is really intriguing in that a master transcription gene \ncompletely restored liver function by rebalancing genetic expression and thus \nproteostasis. \nWhile I don't really need an office at this point, I do need access to a conference room \nfrom time to time and it would be hugely helpful if I could access the foundation's. \nIf there was some work that I could do for the foundation in exchange, I would be \ndelighted to do that. \nIt would be wonderful to catch up with you as well. \nall the best, \nEFTA_R1_01089430 \nEFTA02275606\n", "char_count": 1930}, {"efta_number": "EFTA02275605", "page_number": 2, "text_content": "<1506365439123blobjpg> \n<1506365439123blobjpg><1506365439123blobjpg> \nEFTA_R1_01089431 \nEFTA02275607\n", "char_count": 101}]}